New hope for duchenne boys: experimental drug RAG-18 enters human testing
NCT ID NCT07282652
First seen Dec 26, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage study tests the safety of a new drug, RAG-18, in 12 boys aged 4-15 with Duchenne muscular dystrophy. The drug is given through a vein, and researchers will check for side effects, how the body processes the drug, and whether it helps slow muscle damage. The goal is to find a safe dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, 100730, China
Conditions
Explore the condition pages connected to this study.